ReviewAdvances in ophthalmology practice and research
Recent progress of nanomedicine in managing dry eye disease.
Review in Advances in ophthalmology practice and research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 36 citations in OpenAlex.
- Impact of 0.05% cyclosporine A on visual quality in patients with Post-refractive surgery dry eye.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Trial
- Antioxidant and anti-senescence supramolecular complexes for managing dry eye diseases.Bioactive materials · 2026Article
- Engineering biomimetic tarsal microtissue via structurally zoned hydrogel scaffold for integrated eyelid reconstruction.Bioactive materials · 2026Article
- Development of Imperatorin Nanostructured Lipid Carriers with Grape Seed Oil for Boosting Oral Absorption and Antioxidant Capacity.Molecules (Basel, Switzerland) · 2026Article
- Enhanced ocular delivery of tacrolimus via cationic nanoliposomes: Mitigating inflammation and rebalancing Th17/Treg responses in dry eye disease.Materials today. Bio · 2026Article
- Bridging Therapeutics and Nanotechnology in Dry Eye Disease: A Review of Risk Factors, Drug Delivery Barriers, and Recent and Future Endeavors for Disease Management.AAPS PharmSciTech · 2026Review
- Zinc peroxide-copper bimetallic nanozyme with self-activated ROS and cuproptosis for superficial antifungal therapy.Journal of nanobiotechnology · 2026Article
- Ion‑Responsive in situ Gel of Quercetin‑Loaded PEGylated Liposomes for Anti‑inflammatory Treatment of Dry Eye Disease.International journal of nanomedicine · 2026Article
- ROS-Responsive Cationic Nanoparticles for Cyclosporine A Delivery in Dry Eye Disease: A Dual-Functional Nanotherapeutic Approach.ACS omega · 2025Article
- Cyclic extranasal neurostimulation for dry eye disease: a 4-week stimulation and 6-week intermission regimen based on neural adaptation dynamics.Eye and vision (London, England) · 2025Article
- CuJournal of nanobiotechnology · 2025Article
- Advances in Drug Delivery Science for Diacerein: Strategies to Enhance Solubility, Bioavailability, and Pharmacokinetic Performance.Pharmaceutics · 2025Review
- The microenvironment of ocular surface in keratoconus: a systematic review.Eye and vision (London, England) · 2025Review
- Cyclic cell-penetrating peptide-engineered ceria nanoparticles for non-invasive alleviation of ultraviolet radiation-induced cataract.Journal of nanobiotechnology · 2025Article
- An exploration of the ocular mysteries linking nanoparticles to the patho-therapeutic effects against keratitis.Journal of nanobiotechnology · 2025Review
- Supramolecular Engineering of Nanoceria for Management and Amelioration of Age-Related Macular Degeneration via the Two-Level Blocking of Oxidative Stress and Inflammation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Multifunctional anionic nanoemulsion with linseed oil and lecithin: a preliminary approach for dry eye disease.Beilstein journal of nanotechnology · 2025Article
- Corneal Mucin-Targeting Liposome Nanoplatforms Enable Effective Treatment of Dry Eye Diseases by Integrated Regulation of Ferroptosis and Inflammation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Insular infraorbital neurovascular pedicle labial salivary gland transplantation for the treatment of severe dry eye disease: an IDEAL stage 0, 1 and 2a study.BMJ surgery, interventions, & health technologies · 2025Article
- Recent Achievements and Perspectives in Smart Nano-in-Micro Platforms for Ocular Disease Treatment.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dry eye disease (DED) is a commonly reported ocular complaint that has garnered significant attention in recent research. The global occurrence of DED ranges from 5% to 50%, impacting a substantial proportion of individuals worldwide with increasing frequency. Although topical administration remains the mainstream drug delivery method for ocular diseases, it suffers from drawbacks such as low bioavailability, rapid drug metabolism, and frequent administration requirements. Fortunately, the advancements in nanomedicine offer effective solutions to address the aforementioned issues and provide significant assistance in the treatment of DED. Main text: DED is considered a multifactorial disease of the ocular surface and tear film, in which the integrity of tear film function and structure plays a crucial role in maintaining the homeostasis of the ocular surface. The conventional treatment for DED involves the utilization of artificial tear products, cyclosporin, corticosteroids, mucin secretagogues, and nonsteroidal anti-inflammatory drugs. Furthermore, nanomedicine is presently a significant field of study, with numerous clinical trials underway for various nanotherapeutics including nanoemulsions, nanosuspensions, liposomes, and micelles. Notably, some of these innovative nanoformulations have already received FDA approval as novel remedies for DED, and the advancement of nanomedicine is poised to offer enhanced prospects to solve the shortcomings of existing treatments for DED partially. Conclusions: This article provides an overview of the latest advancements in nanomedicine for DED treatment, while the field of DED treatment is expected to witness a remarkable breakthrough shortly with the development of nanomedicine, bringing promising prospects for patients worldwide suffering conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.